Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy

American Journal of Physiology - Endocrinology and Metabolism

Volumn 290, Issue 2, 2006, Pages

  Hadigan, C ^a   Kamin, D ^a   Liebau, J ^a   Mazza, S ^a   Barrow, S ^a   Torriani, M ^a   Rubin, R ^b   Weise, S ^a   Fischman, A ^a   Grinspoon, S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adipose tissue; Human immunodeficiency virus lipodystrophy; Insulin resistance; Positron emission tomography

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DIET RESTRICTION; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN TISSUE; HYPERINSULINISM; INSULIN SENSITIVITY; LIPOATROPHY; LIPOLYSIS; MALE; METABOLIC PARAMETERS; MUSCLE TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; SKELETAL MUSCLE;

ADIPOSE TISSUE; ADULT; GLUCOSE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; MUSCLE, SKELETAL;

EID: 33644860610     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00273.2005     Document Type: Article

References (54)

1. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, and Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 88: 627-636, 2003.
2. Bashan N, Burdett E, Guma A, Sargeant R, Tumiati L, Liu Z, and Klip A. Mechanisms of adaptation of glucose transporters to changes in the oxidative chain of muscle and fat cells. Am J Physiol Cell Physiol 264: C430-C440, 1993.
3. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P, and Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026-1031, 2002.
4. Behrens GM, Boerner AR, Weber K, van den Hoff J, Ockenga J, Brabant G, and Schmidt RE. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 110: 1319-1327, 2002.
5. Beylot M, Martin C, Beaufrere B, Riou JP, and Mornex R. Determination of steady state and nonsteady-state glycerol kinetics in humans using deuterium-labeled tracer. J Lipid Res 28: 414-422, 1987.
6. Bleeker-Rovers CP, van der Ven AJ, Zomer B, de Geus-Oei LF, Smits P, Corstens FH, Koopmans PP, and Oyen WJ. F-18-fluorodeoxyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patients. AIDS 18: 2430-2432, 2004.
7. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, and Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 36: 172-177, 1982.
8. Caron M, Auclair M, Lagathu C, Lombes A, Walker UA, Kornprobst M, and Capeau J. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 18: 2127-2136, 2004.
9. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, and Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 2093-2099, 1999.
10. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, and Kahn SE. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53: 2087-2094, 2004.
11. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, and Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17: 961-969, 1994.
12. Cherry CL, Lal L, Thompson KA, McLean CA, Ross LL, Hernandez J, Wesselingh SL, and McComsey G. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 38: 263-267, 2005.
13. DeFronzo RA, Tobin JD, and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 237: E214-E223, 1979.
14. Domingo P, Matias-Guiu X, Pujol RM, Francia E, Lagarda E, Sambeat MA, and Vazquez G. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 13: 2261-2267, 1999.
15. Ebert BL, Firth JD, and Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 270: 29083-29089, 1995.
16. Finegood DT, Bergman RN, and Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36: 914-924, 1987.
17. Gan SK, Samaras K, Thompson CH, Kraegen EW, Carr A, Cooper DA, and Chisholm DJ. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 51: 3163-3169., 2002.
18. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 350: 1220-1234, 2004.
19. Guo ZK, Lee WN, Katz J, and Bergner AE. Quantitation of positional isomers of deuterium-labeled glucose by gas chromatography/mass spectrometry. Anal Biochem 204: 273-282, 1992.
20. Hadigan C, Borgonha S, Rabe J, Young V, and Grinspoon S. Increased rates of lipolysis among HIV-infected men receiving highly active antiretroviral therapy. Metabolism 51: 1143-1147, 2002.
21. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB, and Grinspoon S. Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy. Clin Infect Dis 32: 130-139, 2001.
22. Hadigan C, Rabe J, Meininger G, Aliabadi N, Breu J, and Grinspoon S. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am J Clin Nutr 77: 490-494, 2003.
23. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 27: 643-646, 2000.
24. Jan V, Cervera P, Maachi M, Baudrimont M, Kim M, Vidal H, Girard PM, Levan P, Rozenbaum W, Lombes A, Capeau J, and Bastard JP. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 9: 555-564, 2004.
25. Kelley DE, Mintun MA, Watkins SC, Simoneau JA, Jadali F, Fredrickson A, Beattie J, and Theriault R. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 97: 2705-2713, 1996.
26. Kelley DE, Williams KV, Price JC, McKolanis TM, Goodpaster BH, and Thaete FL. Plasma fatty acids, adiposity, and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab 86: 5412-5419, 2001.
27. Levy JC, Brown G, Matthews DR, and Turner RC. Hepatic glucose output in humans measured with labeled glucose to reduce negative errors. Am J Physiol Endocrinol Metab 257: E531-E540, 1989.
28. Luzi L, Perseghin G, Tambussi G, Meneghini E, Scifo P, Pagliato E, Del Maschio A, Testolin G, and Lazzarin A. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 284: E274-E280, 2003.
29. Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, Chisholm D, Samaras K, Emery S, Kelleher A, Cooper DA, and Carr A. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 191: 1686-1696, 2005.
30. Meininger G, Hadigan C, Rietschel P, and Grinspoon S. Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr 76: 460-465, 2002.
31. Molina JM, Baron AD, Edelman SV, Brechtel G, Wallace P, and Olefsky JM. Use of a variable tracer infusion method to determine glucose turnover in humans. Am J Physiol Endocrinol Metab 258: E16-E23, 1990.
32. Murata H, Hruz PW, and Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 16: 859-863, 2002.
33. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, and Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr Hum Retrovirol 31: 514-520, 2002.
34. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, and Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr Hum Retrovirol 25: 312-321, 2000.
35. Nielsen S, Guo Z, Johnson CM, Hensrud DD, and Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 113: 1582-1588, 2004.
36. Nolte LA, Yarasheski KE, Kawanaka K, Fisher J, Le N, and Holloszy JO. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 50: 1397-1401, 2001.
37. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, and Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15: F11-F18, 2001.
38. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M, Bergman J, Solin O, Voipio-Pulkki LM, Wegelius U, and Yki-Järvinen H. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 89: 1767-1774, 1992.
39. Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, and Mallal SA. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther 8: 323-331, 2003.
40. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 85: 4426-4433, 2000.
41. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA, and Touraine JL. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14: 37-49, 2000.
42. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, and Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 15: 1801-1809, 2001.
43. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, and Shinohara M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28: 897-916, 1977.
44. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M, and Yki-Jarvinen H. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16: 2183-2193, 2002.
45. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T, and Yki-Jarvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 88: 1907-1910, 2003.
46. Tong Q, Sankale JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK, and Hotamisligil GS. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 88: 1559-1564, 2003.
47. Torriani M, Hadigan C, Jensen ME, and Grinspoon S. Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome. J Appl Physiol 95: 1005-1010, 2003.
48. Van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, Reiss P, and Sauerwein HP. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15: 2093-2100, 2001.
49. Virtanen KA, Hallsten K, Parkkola R, Janatuinen T, Lonnqvist F, Viljanen T, Ronnemaa T, Knuuti J, Huupponen R, Lonnroth P, and Nuutila P. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52: 283-290, 2003.
50. Virtanen KA, Lonnroth P, Parkkola R, Peltoniemi P, Asola M, Viljanen T, Tolvanen T, Knuuti J, Ronnemaa T, Huupponen R, and Nuutila P. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J Clin Endocrinol Metab 87: 3902-3910, 2002.
51. Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF, and Bergman RN. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 52: 2490-2496, 2003.
52. Wolfe RR, Allsop JR, and Burke JF. Glucose metabolism in man: responses to intravenous glucose infusion. Metab Clin Exper 28: 210-220, 1979.
53. Wolfe RR and Chinkes DL. Calculation of substrate kinetics: single-pool model. In: Istope Tracers in Metabolic Research. Hoboken, NJ: Wiley and Sons, 2005, p. 26-29.
54. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295, 2002.